Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — Investor Presentation (October 2024)
26 slides from Clinuvel Pharmaceuticals's investor presentation, Oct 16, 2024
Slide 1: 16 October 2024
16 October 2024 ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY
Slide 2: Forward-looking statement
Forward-looking statement CLINUVEL GROUP This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to diff
Slide 3: A Patient Centric Approach
A PATIENT CENTRIC APPROACH ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY
Slide 4: Melanocortin House
Melanocortin House Rx Pharmaceutical Markets Specialised Skin Care * SCENESSE® CUV N-AM 100% Polychromatic PHOTOCOSMETICS EPP / VP network EEA 100% Photoprotection P1 N-AM 60–70% I. Selective CUV Repigmentation P2 SOCIAL Vitiligo network distribution Medical Tanning EEA 60–70% MEDIA / channels N-AM
Slide 5: CLINUVEL’s Institutional Ownership
CLINUVEL’s Institutional Ownership % of No. of Institutional Ownership Metric FY2023 (no.) FY2024 (no.) Issued Capital Analysts 35 10 Conferences, webinars, webcasts, Total International Australia Analysts (RHS) 18 25 9 investor briefings, non-deal roadshows 30 8 Investors reached through meetings h
Slide 6: CLINUVEL Share Price vs Fundamentals
CLINUVEL Share Price vs Fundamentals Oct 2019 Sep 2021 50 PE: 120 Share Price, A$ NTA, A$ PE: 87 45 40 35 Jan 2023 PE: 67 30 25 Oct 2024 Apr 2007 20 PE: 20 PE: n.a. 15 Sep 2014 10 PE: n.a. 5 0 Apr 2007 Sep 2014 Oct 2019 Sep 2021 Jan 2023 Oct 2024 Cash: A$8.6m Cash: A$14.6m Cash: A$54.3m Cash: A$82.7
Slide 7: Value to Profitability
Value to Profitability Listed bio-pharmaceuticals with <$5b vs >$5b MCAP RUSSELL 3000 (n=135) + NBI (n=213) + EU Biopharma (n=289) EARNINGS CUV ENTITIES PROFITABLE GROWTH 7-yr BENCHMARKED > $5B 50 35 < $5B 60 30 < $1B 34 13 Total 110 65 Note: Normalised data by log10 transformation, computed Pearson
Slide 8: Correlation between Market Value and Profitability
Correlation between Market Value and Profitability Indicates decoupling between Market Value and Profitability Weak correlation between Market Value and EPS in companies with >$5B MCAP Weak correlation between Market Value and EPS in companies with <$5B MCAP Normalised data by log10 transformation,
Slide 9: Correlation between Market Value and Earnings Growth over 7 Years
Correlation between Market Value and Earnings Growth over 7 Years Indicates decoupling between Market Value and Earnings Growth Weak correlation between Market Value and EBITDA Growth in companies with >$5B MCAP No correlation between Market Value and EBITDA Growth in companies with <$5B MCAP Normal
Slide 10: Emerging value… Catalysts 2024–25
Emerging value… Catalysts 2024–25 EPP: Complete CUV052, re-engage regulators on 1 adolescent use SCENESSE®* 2 VP: regulatory feedback, commence CUV053 SCENESSE® EPP continued growth 3 Stroke: CUV803 results* 4 Vitiligo: CUV105 recruitment* 5 Vitiligo: commence CUV107 study* 6 Establish 120 Specialty
Slide 11: Vitiligo is Unique
VITILIGO IS UNIQUE symptomatology is visible. the negative is visible. treatment effect must provoke a posilive..
Slide 12: New Treatment Algorithm Vitiligo
New Treatment Algorithm Vitiligo NB-UVB Topical Topical JAK Oral JAK SCENESSE® Segmental 10% LOCALISED SYSTEMIC Generalised 90% ✓ ✓ ✓ ✓ ✓ Localisation ✓ ✓ ✓ ✓ Skin Type Fitzpatrick IV – Light Brown ✓ LOCALISED Fitzpatrick V – Brown ✓ Fitzpatrick VI – Black ✓ Systemic ✓ ✓ Disease ✓ ✓ Extent ✓ ✓ ✓ >10
Slide 13: SCENESSE® for vitiligo patients with highest burden
SCENESSE® for vitiligo patients with highest burden ≥ 10% BSA ✓ | F-H-N-genitals ✓ | darker skin complexion (IV-V-VI) ✓
Slide 14: Commercial Infrastructure I
Commercial Infrastructure I North America ACTUAL TARGET Staff 20 27 Distribution Centers 3 2 Shipping 2 3
Slide 15: Commercial Infrastructure II
Commercial Infrastructure II North America ACTUAL TARGET Training / Recommended Clinics 85 120 Average Capacity 50% 50% Patient Fitzpatrick Skin Types IV–VI IV–VI
Slide 16: Commercial Infrastructure III
Commercial Infrastructure III North America ACTUAL TARGET Medicare YES - Medicaid/340B Program YES - Veterans Administration (VA) YES - Commercial Health Insurers YES * *Insurers are familiar with the SCENESSE® implant in dermatology
Slide 17: Commercial Infrastructure IV
Commercial Infrastructure IV North America ACTUAL TARGET J Codes J7352 CPT® Codes 11981 Prior Authorization YES
Slide 18: Commercial Infrastructure V
Commercial Infrastructure V North America – Current Clinics and Targets 71% of target achieved 74% of CUV team established Treatment codes in place 2025-2026 dermatology campaigns OBJECTIVE CLINUVEL to be dominant in North American vitiligo market
Slide 19: Dr Pearl Grimes | Lachlan Hay | Dr Philippe Wolgen
® Dr Pearl Grimes | Lachlan Hay | Dr Philippe Wolgen
Slide 20: Social media = visibility
Social media = visibility January – October 2024 “LADY GAGA EVENT” 2024 MALIBU Impressions 75,346,483 Reach 3.5m Impressions > 11m Instagram views 51,991,821 Attendee followers reach 10.6m Reach 14,132,293 PRESS COVERAGE Profile visits 119,000 The Business of Fashion > 500,000 Hello! Magazine > 7,00
Slide 21: PhotoCosmetics
PhotoCosmetics Acquiring leadership in photomedicine requires maximum visibility in the largest pharmaceutical markets AAD 2025 preparation – 20,000 delegates M-lines disruptive concept
Slide 22: PhotoCosmetics
PhotoCosmetics CLINUVEL as a brand 2024 2026 Q1 Q4 LAUNCH CLINUVEL PROTECT – LAUNCH Polychromatic CLINUVEL LAUNCH Photoprotection Press event (US) PRESERVE – CLINUVEL Radiant/ DNA Times Media (Monaco Ambassador Assisted BRONZE – Summer Focus Malibu E-commerce Social Media Square Film AAD Press Event
Slide 23: Institutional ownership +12.2%; 13 catalysts 2025
Institutional ownership +12.2% – Price vs value decoupled in bio-pharmaceuticals <US$5b – 13 catalysts 2025 (5/16 carried over from 2024) – Vitiligo – commercial preparation N-AM – 75% in place – Social media central in building global CLINUVEL brand – Financial strength provides optionality for 202
Slide 24: In Memory Of
IN MEMORY OF Professor Marcus Maurer – Aug’24
Slide 25: We thank CLINUVEL’s long-term supporters, Board of Directors and staff
We thank CLINUVEL’s long-term supporters, Board of Directors and most of all, our highly committed staff ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY
Slide 26: Authorised for ASX release by the Board of Directors
Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD Head of Investor Relations Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD https://www.clinuvel.com/investors/contact-us www.clinuvel.com Level 22, 535 Bourke Street Melbourne - Victoria, Australia, 3000 T +61 3 9660
Clinuvel Pharmaceuticals — Investor Presentation (October 2024) on 6ix